
STAAR SURGICAL CO
STAANASDAQTrading Snapshot
- Day Range
- $24.85 β $25.29
- 52-Week Range
- $15.59 β $35.87
- Volume
- $2.93B
- Avg Volume
- $3.03B
- Shares Outstanding
- 49.8M
- Next Earnings
- Oct 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $239M
- Last Q Revenue
- $94M
- P/E Ratio
- β
- P/S Ratio
- 4.2x
- EPS (TTM)
- $-0.43
- Dividend Yield
- β
Why Investors Own STAA
- βHigh-growth profile β revenue up +50.6% YoY with expanding US Equity exposure.
- βHealthy economics β 43% gross margin and 25% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About STAAR SURGICAL CO
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
Otter Score Breakdown
βAnalyst Ratings
βLatest News & Updates
STAAR Surgical Appoints Warren Foust As President And CEO, Effective August 4; Names Deborah Andrews EVP And CFO
Deborah Andrews appointed Executive Vice President and Chief Financial OfficerSTAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of
Wedbush Reiterates Outperform on Staar Surgical, Maintains $40 Price Target
Wedbush analyst Michael Piccolo reiterates Staar Surgical (NASDAQ:STAA) with a Outperform and maintains $40 price target.

STAAR Surgical's Punishment For Opacity Is Just
STAAR Surgical Company shares fell sharply after preliminary Q2 2026 sales met expectations but lacked forward guidance. Read more on STAA stock here.

Caution Lingers for STAAR Surgical Amid Middle East Geopolitical Tensions
STAAR Surgical expects preliminary Q2 2026 net sales to top $90 million, driven by strong Americas growth and an inventory rebound in China.

Intuitive Surgical, Netflix And Other Big Stocks Moving Lower In Fridayβs Pre-Market Session
U.S. stock futures lower, Nasdaq 100 down 2%. Intuitive Surgical shares dip 11.3% after Q2 earnings beat estimates. Other stocks also falling in pre-market.

Why Callan JMB Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Callan JMB Inc (CJMB) shares jumped 63.8% in pre-market trading after announcing a strategic partnership with Alabama State University.